[1]向艳,夏劲松.生长抑素类似物及其标记核素[J].国际放射医学核医学杂志,2002,26(1):21-24.
　XIANG Yan,XIA Jin-song.Recent development of radio-labeled somatostatin analogues as receptor image agent[J].International Journal of Radiation Medicine and Nuclear Medicine,2002,26(1):21-24.
点击复制

生长抑素类似物及其标记核素(/HTML)
分享到：

《国际放射医学核医学杂志》[ISSN:1673-4114/CN:12-1381/R]

卷:
26
期数:
2002年第1期
页码:
21-24
栏目:
综述
出版日期:
1900-01-01

文章信息/Info

Title:
Recent development of radio-labeled somatostatin analogues as receptor image agent
作者:
向艳;  夏劲松
430022 武汉, 华中科技大学同济医学院
Author(s):
XIANG Yan;  XIA Jin-song
Xiehe Hospatal, Huazhong University of science and Technoloy, Wuhan 430022, China
关键词:
受体显像; 生长抑素类似物; 核素; 多肽
Keywords:
receptor image; somatostatin analogue; radionuclides; peptide
分类号:
R817.4
摘要:
利用标记小肽进行功能显像有望开创核素显像与肿瘤生物学研究的新纪元。为了提高肿瘤生长抑素受体显像的特异性和敏感性,从受体亚型水平开发受体显像剂,以及研究适合临床应用的简捷标记方法是今后的重要课题。综述了新的核素标记的生长抑素多肽受体配体的研究及其药代动力学性质并评价了其用于肿瘤受体显像的可行性。
Abstract:
The development of radiolabeled peptide-based radiopharmaceuticals for imaging a variety of tumors has seen a new era in nuclear medicine.Recently, a number of radio-labeled somatostatin analogues have proven to be useful diagnostic imaging agents.The challenge is to synthesize a wide range of biologically active somatostatin analogue peptides without affecting their receptor binding properties, and label bioactive peptides with radionuclides with high specific activity without impairing the biological properties of the peptides.This review presents recent developments in radio-labeled somatostatin analogues and their pharmacokinetic properties, their potential as diagnostic imaging agents are also addressed.

参考文献/References:

[1] Kwekkeboom D, Krenning EP, de Jong M. Peptide receptor imaging and therapy[J].J Nucl Med, 2000, 41(10):1704-1713.
[2] Slooter GD, Mearadji A, Breeman WA, et al. Somatostatin receptor imaging, therapy and new strategies in patient with neuroendocrine tumours[J]. Br J Surg, 2001, 88(1):31-40.
[3] Chiti A, Briganti V, Fanti S, et al. Results and potential of somatostatin receptor imaging in gastroenteropancreatic tract tumours[J]. Q J Nucl Med, 2000, 44(1):42-49.
[4] Kurtaran A, Ofluoglu S, Traub T, et al.An unusual visualization of the gallbladder by somatostatin receptor (SSTR) scintigraphy:usefulness of hepatobiliary imaging for differential diagnosis[J]. Am J Gastroenterol, 2000,95(5):1367-1368.
[5] Forssell-Aronsson EB, Nilsson O, Bejegard SA, et al.111In-DTPA-D-Phel-octreotide binding and somatostatin recoptor subtypes in thyroid tumors[J]. J Nucl Med,2000,41(4):636-642.
[6] Breeman WA,Hofland LJ,van der Phuijm M,et al.A new adiolabelled somatostatin analogue[111In-DTPA-D-Phe1] RC-160:preparation, biological activity, receptor scintigraphy in rats and comparison with[111In-DTPA-D-Phe1] octreotide[J]. Eur J Nucl Med, 1994, 21(4):328-335.
[7] Ander CJ,Dehdashti F,Cctler PD, et al.64Cu-TETA-octreotide as a PET imaging agent for patiengs with neuroendocrine tumor[J]. J Nucl Med,2001,42(20):213-221.
[8] Bakker WH, Breeman WA, van der Pluijm ME, et al. Iodine-131 labelled octreotide:not an option for somatostatin receptor therapy[J]. Eur J Nucl Med, 1996, 23(7):775-781.
[9] Krenning EP, Valkema R, Kooij PP, et al. The role of radioactive somatostatin and its analogues in the control oftumor growth[J]. Recent Results Cancer Res, 2000, 153:1-13.
[10] BugaJ JE, Erion JL, Johnson MA, et al. Radiothapeutic efficacy of (153) Sm-CMBTPA-Tyr(3)-octreotate in tumor-bearing rats * (1)[J]. Nucl Med Biol, 2001, 28(3):327-334.
[11] Liste James J, Moyer BR, Dean T, et al. Small peptides radiolabeled with 99Tcm[J]. Q J Nucl Med, 1996, 40(3):221-233.
[12] Lister-James J, Moyer BR, Dean T. Pharmacokinetic considerations in the development of peptide-basedimaging agents[J]. Q J Nucl Med. 1997,41(2):111-118.
[13] Decristoforo C, Mather S J, et al, Preparation, 99Tem-labeling, and in vitro characteization of HYNIC and N3S modified RC-160 and[Tyr3] octreotide[J]. Bioconjug Chem, 1999, 10(3):144-150.
[14] Kolan H, Li J, Thakur ML. Sandostatin labeled with 99Tcm:in vitro stability, in vivo validity and comparisonwith 111In-DTPA-octreotide[J].Pept Res, 1996, 9(3):144-150.
[15] Bangard M, Behe M, Guhlke S, et al. Detection of somatostatin receptor-positive tumours using the new 99Tcm-tricine-HY-NIC-D-Phe1-Tyr3-octreotide:first results in patientsandcomparison with 111In-DTPA-D-Phel-Tyr3-octreotide:first results in patients and comparison with 111In-DTPA-D-Phel-octretide[J]. Eur J Nucl Med, 2000, 27(6):628-637.
[16] Spradau TW, Edwards WB, Anderson CJ, et al. Synthesis and biologcal evaluation of Tc-99m-cyclopentadienyltricarbon-bonyltechnetium-labeled octreotide[J]. Nucl Med Biol, 199926(1):1-7.

相似文献/References:

[1]邱春,管一晖.5-羟色胺受体显像剂在神经系统疾病及脑功能研究中的应用[J].国际放射医学核医学杂志,2011,35(2):73.[doi:10.3760/cma.j.issn.1673-4114.2011.02.003]
　QIU Chun,GUAN Yi-hui.Application of 5-hydroxytryptamine receptor imaging for study of neuropsychiatric disorders and brain functions[J].International Journal of Radiation Medicine and Nuclear Medicine,2011,35(1):73.[doi:10.3760/cma.j.issn.1673-4114.2011.02.003]
[2]江波,刘璐.多肽类示踪技术在乳腺癌诊治中的应用进展[J].国际放射医学核医学杂志,2009,33(1):5.[doi:10.3760/cma.j.issn.1673-4114.2009.01.005]
　JIANG Bo,LIU Lu.Application researched progress of micromolecule polypeptide technology in diagnosis and therapy of breast cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2009,33(1):5.[doi:10.3760/cma.j.issn.1673-4114.2009.01.005]
[3]段炼,李险峰.甲状腺相关眼病与生长抑素受体显像[J].国际放射医学核医学杂志,2005,29(3):108.
　DUAN Lian,LI Xian-feng.Thyroid associated ophthalmopathy and somatostatin receptor scintigraphy[J].International Journal of Radiation Medicine and Nuclear Medicine,2005,29(1):108.
[4]赵德善.放射性核素标记生长抑素类似物在淋巴瘤中的应用[J].国际放射医学核医学杂志,2004,28(5):206.
　ZHAO De-shan.The role of radionuclide-labeled somatostatin analogues in lymphoma[J].International Journal of Radiation Medicine and Nuclear Medicine,2004,28(1):206.
[5]张军.11C-flumazenil受体显像在缺血半暗带研究中的进展[J].国际放射医学核医学杂志,2004,28(6):246.
　ZHANG Jun.Advances of 11C-flumazenil receptor imaging in ischemic penumbra[J].International Journal of Radiation Medicine and Nuclear Medicine,2004,28(1):246.
[6]邢诗安.叶酸受体及其在肿瘤核医学中的应用[J].国际放射医学核医学杂志,2002,26(6):257.
　XING Shi-an.Folate receptor and the application in tumor nuclear medicine[J].International Journal of Radiation Medicine and Nuclear Medicine,2002,26(1):257.
[7]王雪鹃,张梅颖,林保和.肿瘤血管活性肠肽受体显像[J].国际放射医学核医学杂志,2001,25(2):65.
　WANG Xue-juan,ZHANG Mei-ying,LIN Bao-he.Tumor imaging of vasoactive intestinal peptide receptor[J].International Journal of Radiation Medicine and Nuclear Medicine,2001,25(1):65.
[8]张春丽,王荣福.肿瘤受体显像[J].国际放射医学核医学杂志,2000,24(3):124.
　ZHANG Chun-li,WANG Rong-fu.Tumor receptor imaging[J].International Journal of Radiation Medicine and Nuclear Medicine,2000,24(1):124.
[9]武鸿文,管昌田.99mTc标记生长抑素类似物作为受体显像剂及其特性研究[J].国际放射医学核医学杂志,1998,22(4):158.
[10]王文明,刘秀杰.核心脏病学非灌注显像技术的临床应用进展[J].国际放射医学核医学杂志,1998,22(5):197.

备注/Memo

备注/Memo:
收稿日期:2001-7-20。
作者简介:向艳(1973-),女,湖北宜昌人,硕士研究生,主要从事妇科肿瘤及不孕症的研究。;夏劲松(1973-),男,湖北通山人,博士研究生,主要从事特异性靶向药物的研究和肿瘤核医学的研究。
更新日期/Last Update: 1900-01-01